BioSig Technologies Inc, the medtech group, has announced another boost for its heart monitoring technology, revealing that the US Patent Office had awarded patent claims for its PURE EP noise-filtering technology.
The patent application was filed on November 6 last year and describes and claims computer-implemented methods for filtering noise from an input signal.
It means the company now has 49 issued or allowed worldwide patents covering its novel technology for arrhythmia (abnormality of a heartbeat) care.
BioSig explained that some current electrophysiology (EP) recording systems can effectively support the treatment of arrhythmias such as atrial flutter and supraventricular tachycardia, which show up as large-amplitude, low-frequency signals.
But more complex and prevalent arrhythmias, such as atrial fibrillation and ventricular tachycardia, characterized by low-amplitude, high-frequency signals, have not found an effective evaluation of all relevant signals.
READ: BioSig Technologies selects Access Strategy Partners to accelerate commercial sales
The company's patented PURE EP System can record raw (unaltered) cardiac and other physiologic signals with multiple display options, low noise, and a large input signal dynamic range.
The tech can also provide large-signal (eg: from a defibrillator) input protection and radio frequency (RF) signal (eg: from ablation) noise suppression.
"We are pleased to announce this newest patent allowance which demonstrates the clinical significance of our PURE EP System in filtering noise from complex signals in the EP setting," said Kenneth L. Londoner, CEO of BioSig Technologies, in a statement.
"We believe we have the leading patent-protected solution for providing superior intracardiac signal information to electrophysiologists during catheter ablation procedures across all types of cardiac arrhythmias."
BioSig Technologies shares nudged up 3.4% in New York to $1.83 each.
Contact the writer at giles@proactiveinvestors.com